AveXis receives FDA approval for Zolgensma, the first and only gene therapy for pediatric patients…
AveXis, a Novartis company, announced the US Food and Drug Administration (FDA) has approved Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than…
Read More...
Read More...